Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reagan’s Impact On User Fee Dates

This article was originally published in The Pink Sheet Daily

Executive Summary

CBER is treating June 11 as a holiday and will not extend any user fee dates. CDER is treating the office closure like any other (e.g. weather) and may extend user fee goals that fall near the date on a case-by-case basis.

You may also be interested in...



FDA Should Consider CFC Albuterol Phase-Out Date Beyond 2005 – Cmte.

Committee expresses concern about availability of albuterol HFA supply on chlorofluorocarbon phase-out date. Schering-Plough and GSK tell FDA it will take up to 18 months to expand annual production capacity to 30 mil. doses each.

FDA Cancels Meetings On Day Of Mourning For Reagan

Part 11 meeting on June 11 is cancelled and will not be rescheduled. The Anthrax Targeted Therapy Development workshop is rescheduled to begin and conclude on June 10 instead of running for two days.

Cardiome Oxyprim, Chronic Gout Drug Trials May Use Surrogate Endpoints For Approval, Cmte. Says

Surrogate endpoint should seek a reduction in serum uric acid to a level of 6 mg/dL. Clinical outcome trials to confirm benefits of chronic gout products through reduction in gouty attacks should be carried out post-approval.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel